Search

24 Jul 2024: doi:A structure-guided molecular chaperone approach for restoring the transcriptional activity of the p53 cancer mutant Y220C. ... Cancers. (2019). 11,. 1151. (doi:Aminobenzothiazole derivatives stabilize the thermolabile p53 cancer mutant Y220C and show

24 Jul 2024: Chiba Ene (PhD Medical Sciences) - Histone demethylase Jumonji D3 (JMJD3) as a Tumor Suppressor by Regulating p53 Activity through Lysine Demethylation.

24 Jul 2024: We focus on how mutation affects proteins in the cell cycle, particularly the tumour suppressor p53, in order to design novel anti-cancer drugs that function by restoring the activity of ... Cancer is a disease of mutation, and the most commonly mutated

11 Jun 2018: Absence of p53 in cells makes them more likely to become tumorous as damage can no longer be corrected. ... The team found that by decreasing activity of p53 in a cell, they could more efficiently edit healthy cells.

26 Jan 2021: We focus on how mutation affects proteins in the cell cycle, particularly the tumour suppressor p53, in order to design novel anti-cancer drugs that function by restoring the activity of ... Tumour Suppressor p53. Structural Biology and Drug Discovery.

23 Feb 2024: Mdm2 is critically and continuously required to suppress lethal p53 activity in vivo. ... Cancer Cell, 2006. 10(6): p. 501-14 PMID:17157790. Christophorou MA, Ringshausen I, Finch AJ, Swigart LB, Evan GI The pathological response to DNA damage does not

23 Feb 2024: Multi-omics reveals clinically relevant proliferative drive associated with mTOR-MYC-OXPHOS activity in chronic lymphocytic leukemia. ... Swigart, and G.I. Evan. Mdm2 is critically and continuously required to suppress lethal p53 activity in vivo.

21 Jul 2023: We focus on how mutation affects proteins in the cell cycle, particularly the tumour suppressor p53, in order to design novel anti-cancer drugs that function by restoring the activity of ... Exploiting Transient Protein States for the Design of

We focus on how mutation affects proteins in the cell cycle, particularly the tumour suppressor p53, in order to design novel anti-cancer drugs that function by restoring the activity of ... n. Cancer is a disease of mutation, and the most commonly

23 Feb 2024: Lab Investigation doi: 10.1038/labinvest.2011.96 . McDuff F.K.E and Turner S.D.(2011) Aberrant Anaplastic Lymphoma Kinase Activity Induces a p53 and Rb-Dependent Senescence-Like Arrest ... Merkel, O., Morrigl, R.,Turner, S.D. and Kenner, L. (2017)